Vaxart, Inc.

The post Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference appeared first on Vaxart Inc..

The post Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology appeared first on Vaxart Inc..

The post Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results appeared first on Vaxart Inc..

The post Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET appeared first on Vaxart Inc..

The post Vaxart Announces Results of Annual Meeting of Stockholders appeared first on Vaxart Inc..

The post Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine appeared first on Vaxart Inc..

The post Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements appeared first on Vaxart Inc..

The post Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY appeared first on Vaxart Inc..

The post Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting appeared first on Vaxart Inc..

The post Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY appeared first on Vaxart Inc..